Five peptides dominate the current evidence base for skin repair research in Australia: GHK-Cu, BPC-157, TB500 (thymosin β4 analogue), Melanotan II (melanocortin agonist), and glutathione. Each operates through a distinct molecular mechanism, copper-mediated collagen gene upregulation, actin-sequestration-driven fibroblast migration, and so on, so peptide selection comes down to target pathway, not brand preference.
GHK-Cu is a tripeptide found naturally in human plasma. At concentrations of 0.01–100 nM it increases collagen I and III gene expression in dermal fibroblasts, alongside decorin and glycosaminoglycan synthesis. Glutathione down-regulates melanogenesis by inhibiting tyrosinase and shifting the pheomelanin/eumelanin ratio.
The five best-researched peptides for skin repair in Australia (2026):
- GHK-Cu, collagen I/III upregulation, matrix metalloproteinase (MMP) modulation, antioxidant signalling
- BPC-157, preclinical wound-closure and angiogenesis activity at nanomolar–micromolar concentrations
- TB500 (thymosin β4 analogue), G-actin sequestration, fibroblast motility, wound closure
- Melanotan II, melanocortin-1 receptor (MC1R) agonist; activates the cyclic adenosine monophosphate (cAMP)–protein kinase A (PKA)–microphthalmia-associated transcription factor (MITF) cascade to drive eumelanin synthesis
- Glutathione, tyrosinase inhibition, nuclear factor erythroid 2-related factor 2 (Nrf2) activation, melanin modulation
The Therapeutic Goods Administration (TGA) classifies how each peptide may be sourced and used in Australia.
Why Peptides Matter for Skin Research
Peptides are intercellular signalling molecules. They bind to surface receptors on dermal fibroblasts and keratinocytes, triggering downstream transcription of structural proteins including collagen I, collagen III, and elastin. Their molecular weight, typically 500–5,000 Da, sits between small-molecule drugs and full proteins, which supports measurable tissue penetration in ex vivo skin models without the immunogenicity risks associated with larger biologics.
Collagen Synthesis and Fibroblast Activation
Collagen biosynthesis depends on a tightly regulated sequence: fibroblast activation, procollagen transcription, hydroxylation of proline and lysine residues, and enzymatic cross-linking in the extracellular matrix. Peptides that engage transforming growth factor-beta (TGF-β) receptors or copper-binding sites on fibroblast membranes can accelerate early steps in this sequence. GHK-Cu, for example, increases collagen I and III gene expression in human dermal fibroblasts at concentrations as low as 0.01 nM, alongside upregulation of decorin and glycosaminoglycan synthesis. These findings, established in the Pickart and Margolina corpus (2018), remain the mechanistic foundation for copper peptide research, though large-scale human collagen-synthesis trials from 2024–2026 have not yet been published.
Fibroblast motility is a separate but related variable. Peptides that modulate actin polymerisation, such as thymosin β4 analogues, sequester G-actin monomers in a 1:1 stoichiometry, reducing filament assembly and enabling the cytoskeletal reorganisation required for directed cell migration toward wound sites.
Oxidative Stress and Melanin Pathways
Reactive oxygen species generated during ultraviolet (UV) exposure and inflammatory signalling suppress fibroblast proliferation and accelerate collagen degradation via matrix metalloproteinase upregulation. Glutathione counters this through Nrf2 pathway activation and direct tyrosinase inhibition, shifting melanin synthesis toward pheomelanin and reducing oxidative load in melanocytes.
BPC-157 adds another dimension. Preclinical models show angiogenic signalling at nanomolar-to-micromolar concentrations, supporting the vascular component of tissue repair that collagen-focused studies often underweight.
Peptides are a signalling molecule class, not a monolithic treatment category. Each sequence targets a distinct receptor or enzymatic pathway, which is why mechanism-of-action clarity is the prerequisite for any meaningful research design.
GHK-Cu: The Copper Tripeptide for Collagen Synthesis
GHK-Cu (glycine-histidine-lysine complexed with copper(II)) is a naturally occurring human plasma tripeptide that upregulates collagen I and III gene expression in dermal fibroblasts, with documented activity at concentrations as low as 0.01 nM in cell-culture models.
Mechanism of Action
The copper ion is not incidental to GHK's function; it is structurally required. Copper(II) coordinates with the histidine imidazole ring and the glycine amino terminus, forming a stable square-planar complex that enables cellular uptake via copper transporter proteins and subsequent interaction with fibroblast signalling cascades. Once internalised, GHK-Cu modulates the TGF-β pathway, suppresses matrix metalloproteinase activity, and increases decorin and glycosaminoglycan synthesis alongside collagen I and III. That multi-target profile distinguishes it from single-pathway collagen stimulants.
Research Evidence and Concentrations
The foundational and recent literature points to several consistent findings.
Fibroblast collagen synthesis increases across a concentration range of 0.01 nM to 100 nM in human dermal fibroblast cultures, with elastin and fibronectin co-upregulation observed at the higher end of this range. Topical GHK-Cu application in human skin studies increased dermal collagen thickness and density, with histological confirmation in multiple independent models. In vitro wound-healing assays typically employ 1–10 µg/mL as working concentrations, though exact values are model-dependent and should not be extrapolated to clinical dosing.
A 2023 formulation study in Journal of Molecular Liquids examined GHK-Cu ionic liquid microemulsions for improved dermal delivery, focusing on stability and penetration rather than collagen endpoints. The Pickart and Margolina 2018 Biomedicines review remains the most-cited mechanistic reference. No comparable large-scale human collagen-synthesis trial has been published between 2024 and 2026.
Regulatory and Purity Context in Australia
In Australian research settings, GHK-Cu sourced for laboratory use falls under chemical supplier standards rather than TGA medicines regulation, provided it is not administered to humans. Any clinical application requires either Australian Register of Therapeutic Goods (ARTG) listing or access through the Special Access Scheme or Authorised Prescriber pathway, with Good Manufacturing Practice (GMP)-verified purity (typically ≥95% by high-performance liquid chromatography (HPLC)) and full batch traceability.
Researchers comparing GHK-Cu's angiogenic and repair signalling with peptides such as BPC-157 or cytoskeletal modulators like TB500 should note that each operates through a distinct receptor class. Cross-peptide comparisons are only meaningful when concentration ranges and assay conditions are matched.
BPC-157: Tissue Repair and Growth-Factor Signalling
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence of human gastric juice protein BPC, studied primarily for its capacity to accelerate tissue repair through modulation of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) signalling pathways.
Research on BPC-157 in wound-healing models consistently places it within the broader category of cytoprotective and angiogenic peptides. Its proposed mechanism centres on upregulating VEGF receptor expression, promoting neovascularisation at wound sites, and stimulating fibroblast migration, the cellular process that underpins dermal matrix remodelling and wound closure. In vitro work on non-cutaneous cell lines has demonstrated activity across the 10⁻⁹–10⁻⁶ M concentration range, and 2024–2025 dermatology-adjacent studies suggest dermal models use approximately 0.1–10 µM as working concentrations, though these figures are model-dependent and for fibroblast-specific assays.
Structural and Signalling Context
BPC-157 does not bind a single characterised receptor with the specificity of a classical ligand-receptor pair. Current structural genomics data indicate it interacts with growth-factor receptor cascades indirectly, influencing downstream extracellular signal-regulated kinase 1/2 (ERK1/2) and focal adhesion kinase (FAK) phosphorylation associated with cell motility. That positions it mechanistically alongside, but distinct from, actin-cytoskeletal modulators such as TB500, where fibroblast migration is driven by G-actin sequestration rather than growth-factor receptor cross-talk.
Several points from the current research record warrant attention:
- BPC-157 is a 15-amino-acid peptide with a proposed mechanism involving VEGF and FGF pathway modulation, supported by animal wound-closure models
- In vitro concentration ranges of approximately 0.1–10 µM are reported across tissue-repair studies; these are preclinical figures and must not be extrapolated to human dosing
- 2024–2025 dermatology-specific fibroblast data remain sparse; most mechanistic evidence is embedded in broader gastrointestinal and musculoskeletal repair models
- No TGA-approved dermatologic indication exists for BPC-157 in Australia; it is classified as an unapproved therapeutic good, accessible only through the Special Access Scheme or Authorised Prescriber pathway for human use
- Research-grade BPC-157 sourced for laboratory use falls under chemical supplier and workplace safety standards, not TGA medicines regulation
TB500 (Thymosin Beta 4): Actin-Binding and Cellular Migration
TB500 is a research designation for synthetic fragments and analogues of thymosin β4, a 43-amino-acid protein whose capacity to sequester G-actin monomers in a 1:1 stoichiometric complex underpins its role in fibroblast and keratinocyte migration. By binding G-actin, thymosin β4 reduces the pool available for filament polymerisation, modulating cytoskeletal dynamics in a way that promotes cell motility rather than structural rigidity. This mechanism is distinct from the growth-factor receptor cross-talk examined in BPC-157 profiles, where ERK1/2 and FAK phosphorylation drive migration through VEGF and FGF signalling.
Mechanism in Skin-Cell Repair
Pre-2023 crystallographic models established the structural basis for thymosin β4–G-actin binding. Cell-migration papers published between 2023 and 2025 extend this foundation, linking actin-monomer sequestration to enhanced fibroblast motility and accelerated wound closure in animal models. TB500 is inferred to share thymosin β4's actin-binding functional motif, the LKKTET sequence, though no 2024–2026 cryo-electron microscopy (cryo-EM) or crystallographic study has resolved a TB500-specific complex at high resolution. Any structural claims specific to TB500 rather than the parent protein remain extrapolations from thymosin β4 data.
Beyond fibroblast migration, thymosin β4 research associates actin-pathway modulation with keratinocyte recruitment and angiogenic support, both relevant to dermal repair models. Animal wound-healing assays, the primary experimental context for TB500, typically run for 7–28 days and employ peptide concentrations in the low-micromolar range, consistent with the broader thymosin β4 literature.
Current research findings on TB500 and actin dynamics:
- TB500 is a thymosin β4-mimetic; its actin-binding properties are inferred from thymosin β4 structural data showing 1:1 G-actin stoichiometry
- 2023–2025 wound-healing studies report enhanced fibroblast motility linked to actin-monomer sequestration, though these studies examine thymosin β4 rather than TB500 directly
- Animal repair models typically use low-micromolar peptide concentrations over 7–28 day observation windows; these are preclinical figures only
- No 2024–2026 cryo-EM or crystallographic study has resolved a TB500-specific actin complex; TB500-specific structural claims are unverified extrapolations
- TB500 is classified as an unapproved therapeutic good in Australia; human use requires access through the TGA Special Access Scheme or Authorised Prescriber pathway
- Research-grade TB500 used in laboratory settings is governed by chemical supplier standards and workplace safety law, not TGA medicines regulation
Glutathione: Antioxidant and Skin-Brightening Research
Glutathione (γ-glutamyl-cysteinyl-glycine) is a tripeptide that down-regulates melanogenesis in human melanocytes primarily by inhibiting tyrosinase activity, shifting the pheomelanin/eumelanin balance, and modulating MITF-related transcription factors through redox-sensitive signalling.
Mechanism of Action
Reduced glutathione (GSH) is the cell's principal intracellular antioxidant, neutralising reactive oxygen species that would otherwise activate melanin-synthesis cascades. By sequestering copper ions at the tyrosinase active site and reducing oxidised tyrosinase intermediates, GSH suppresses both the rate-limiting step of melanin production and downstream eumelanin polymerisation. 2023–2024 work also implicates Nrf2 activation and cross-talk with cysteine and glutamate transporters as secondary regulatory nodes, though the core tyrosinase-inhibition mechanism remains consistent with pre-2020 findings.
Skin-Brightening Research Findings
A 2023–2024 cluster of in vitro and ex vivo studies in Asian and European dermatology journals reported dose-dependent reductions in tyrosinase activity and melanin content in cultured human melanocytes and reconstructed epidermis models treated with GSH and GSH-conjugates. Small human trials using oral or intravenous glutathione reported visible brightening outcomes, though several 2024 regulatory and ethics commentaries flagged safety and efficacy concerns specific to parenteral administration.
Key research parameters and regulatory considerations for Australian contexts:
- Glutathione is a tripeptide (γ-glutamyl-cysteinyl-glycine) with a molecular weight of approximately 307 Da; its hydrophilic structure limits transdermal penetration, making bioavailability a persistent challenge for topical formulations
- In vitro studies use GSH concentrations in the micromolar-to-millimolar range; these are cell-culture figures, not clinical dosing references
- Oral glutathione bioavailability is debated; 2023–2024 studies report partial absorption via intestinal transport, but systemic GSH elevation from oral dosing remains inconsistent across subjects
- Parenteral glutathione for cosmetic skin brightening is not TGA-approved; the TGA has issued warnings against intravenous "skin whitening" infusions, classifying them as unapproved therapeutic goods
- Compounding pharmacies supplying glutathione for human use in Australia must operate under state and territory poisons legislation and TGA compounding frameworks
Research-grade glutathione used in laboratory assays falls under chemical supplier standards and workplace safety law rather than TGA medicines regulation, the same framework that applies to other preclinical peptides such as BPC-157. Any transition from bench-level assay work to human administration requires engagement with TGA approval pathways.
Melanotan II: Melanocortin Agonist and Pigmentation Research
Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH) that acts as a potent agonist at the melanocortin-1 receptor (MC1R), triggering the intracellular cAMP cascade that drives melanin synthesis in melanocytes.
Mechanism: MC1R Agonism and Melanogenesis
MC1R is a G protein-coupled receptor expressed on melanocytes; its activation by α-MSH or MT-II stimulates adenylyl cyclase, elevates cyclic adenosine monophosphate (cAMP), and upregulates microphthalmia-associated transcription factor (MITF), which in turn increases transcription of tyrosinase and related enzymes responsible for eumelanin production. MT-II binds MC1R with higher affinity than the endogenous ligand α-MSH, a property attributed to its cyclic conformation constraining the pharmacophoric His-Phe-Arg-Trp motif in a receptor-complementary geometry.
Key parameters from pigmentation research models:
- MT-II demonstrates MC1R binding affinity (Ki) in the low nanomolar range in competitive radioligand assays, with receptor activation reported at concentrations of approximately 1–10 nM in cultured human melanocyte models
- In vitro melanogenesis studies from 2023–2024 show dose-dependent increases in melanin content and tyrosinase activity in human melanocyte cell lines at MT-II concentrations of 10–100 nM
- Structural genomics work on melanocortin receptor subtypes (MC1R through MC5R), including data from the Joint Center for Structural Genomics (JCSG), continues to inform selectivity profiling; MT-II's limited subtype selectivity, with activity at MC3R and MC4R as well as MC1R, is a recognised confound in pigmentation-specific research models
- Pigmentation assays using reconstructed human epidermis have been used to quantify eumelanin/pheomelanin ratios following MT-II exposure, providing a more physiologically relevant model than monolayer melanocyte culture
Australian Regulatory Status
The TGA classifies Melanotan II as an unapproved therapeutic good. Advertising or supplying MT-II for human use in Australia without ARTG listing or an applicable Special Access Scheme authorisation breaches the Therapeutic Goods Act 1989. The TGA issued specific consumer warnings against MT-II peptide injections in 2023, citing risks of contamination, cardiovascular effects, and uncontrolled melanocytic activity. Research-grade MT-II handled in a laboratory setting falls under chemical supplier and workplace safety frameworks, not TGA medicines regulation, consistent with the preclinical classification applied to other research peptides covered in this article.
Comparing Skin-Repair Peptides: Mechanism and Research Focus
Each of the five peptides profiled here targets a distinct biological pathway, making mechanism the primary variable when selecting a model for preclinical skin-repair research.
| Peptide | Primary Mechanism | Target Pathway | Typical Research Concentration | Key Research Application |
|---|---|---|---|---|
| GHK-Cu | Upregulates collagen I/III gene expression; modulates MMPs and decorin synthesis | Collagen/extracellular matrix (ECM) remodelling | 0.01–100 nM (human dermal fibroblasts) | Fibroblast collagen and elastin production; wound-healing models |
| BPC-157 | Promotes angiogenesis; cytoprotective signalling via VEGF and nitric oxide pathways | Tissue repair and vascularisation | 0.1–10 µM (in vitro wound models) | Dermal repair assays; preclinical sourcing and purity context |
| TB500 | Thymosin β4-mimetic; sequesters G-actin monomers (1:1 stoichiometry), regulating polymerisation and fibroblast motility | Cytoskeletal dynamics and cell migration | Inferred from thymosin β4 cell-migration studies; TB500-specific concentrations unverified | Fibroblast migration assays; wound-closure models |
| Glutathione | Inhibits tyrosinase activity; shifts eumelanin/pheomelanin balance via redox signalling and Nrf2 activation | Antioxidant and melanogenesis regulation | Dose-dependent reductions in tyrosinase activity reported across nanomolar–micromolar ranges in cultured melanocytes | Melanin-modulation assays; oxidative-stress models in reconstructed epidermis |
| Melanotan II | MC1R agonist (also active at MC3R/MC4R); activates cAMP-PKA-MITF cascade to stimulate melanogenesis | Pigmentation and melanocortin signalling | 10–100 nM (in vitro melanocyte cell lines, 2023–2024) | Melanogenesis quantification; eumelanin/pheomelanin ratio studies |
Selecting a Model Based on Research Question
Four practical distinctions guide peptide selection:
- Collagen and ECM endpoints, GHK-Cu at 0.01–100 nM remains the most characterised option, with a 50-year mechanistic corpus anchored in human dermal fibroblast data.
- Cell migration and wound closure, TB500 (as a thymosin β4-mimetic) and BPC-157 address complementary aspects: cytoskeletal actin dynamics versus angiogenic and cytoprotective signalling, respectively.
- Pigmentation and antioxidant pathways, Glutathione and Melanotan II operate on opposing ends of melanogenesis; glutathione suppresses tyrosinase activity, while MT-II activates the MC1R-cAMP axis to drive melanin synthesis.
- Selectivity profiling, Structural genomics datasets from JCSG and related programmes provide receptor-subtype binding data that inform which peptide is appropriate when off-target activity at related receptor subtypes would confound results.
GHK-Cu is a copper-binding tripeptide (Gly-His-Lys) that increases collagen and elastin production in human dermal fibroblasts at concentrations as low as 0.01 nM. All five peptides remain research-grade compounds in Australia, with no TGA-approved dermatologic indication for any of them as of 2026.
Research Purity, Sourcing, and Quality in Australia
Peptide quality is the single most consequential variable in any skin-repair research programme. In Australia, the regulatory boundary between a legitimate research reagent and an unapproved therapeutic good is clearly drawn by the TGA.
GMP vs Research-Grade: A Regulatory Distinction That Matters
The TGA classifies peptides such as GHK-Cu, BPC-157, TB500, and Melanotan II as prescription-only medicines or unapproved therapeutic goods when supplied for human administration. Any peptide intended for clinical use must either hold an ARTG listing or be accessed through the Special Access Scheme (SAS) or Authorised Prescriber pathway, with compounding subject to state and territory poisons legislation. Peptides manufactured for human use must meet Pharmaceutical Inspection Cooperation Scheme (PIC/S)-aligned GMP standards, including HPLC-verified purity (commonly ≥95–98%), residual solvent limits, endotoxin testing for parenteral preparations, and full batch traceability.
Research-grade peptides used in non-clinical laboratory settings sit outside TGA medicines regulation and are instead governed by chemical supplier standards and workplace safety law. Repurposing research-grade reagents for human administration is not compliant with TGA requirements. Promoting Schedule 4 peptides to the public for self-administration breaches TGA advertising regulations.
Sourcing and Third-Party Verification
For preclinical in vitro work, researchers should request certificates of analysis confirming purity by HPLC, mass spectrometry confirmation of molecular identity, and lot-specific data. Suppliers such as JCSG and Body Pharm Australia supply research-grade peptides to the Australian market with documented analytical data. Researchers investigating BPC-157 or TB500 should verify that each batch includes third-party HPLC and mass spectrometry reports before use in cell-culture or animal models.
Storage and Stability Considerations
Lyophilised peptides should be stored at −20 °C and protected from repeated freeze-thaw cycles; reconstituted solutions are typically stable for 7–14 days at 4 °C depending on the peptide and solvent system. Copper-chelating peptides such as GHK-Cu are particularly sensitive to oxidative degradation and require inert-atmosphere handling once reconstituted. Stability data should be confirmed with the supplier for each specific lot.
How to Use These Peptides in Skin-Repair Research
Selecting the right experimental model and concentration range is the first decision point in any peptide skin-repair study. The choice between in vitro and in vivo systems determines which endpoints are measurable, which controls are valid, and how far findings can be extrapolated.
In Vitro Model Selection
Primary human dermal fibroblasts (HDFs) and reconstructed full-thickness skin equivalents are the standard starting points for collagen-synthesis and cell-migration work. HDF monolayer cultures allow rapid dose-response characterisation. Three-dimensional (3D) skin equivalents better replicate the extracellular matrix environment relevant to wound closure. Scratch-assay and transwell migration protocols remain the most widely used methods for quantifying fibroblast motility in response to peptide treatment.
Typical Research Concentrations and Exposure Times
GHK-Cu is active across a wide concentration window in fibroblast culture. Experimental work has used 0.01–100 nM for gene-expression endpoints (collagen I/III, decorin, glycosaminoglycans) and 1–10 µg/mL for morphological and proliferation assays, with 24–72-hour exposure periods being standard. BPC-157 studies in wound-healing models report activity in the 10⁻⁹–10⁻⁶ M range; dermal-specific work extrapolates concentrations of approximately 0.1–1 µg/mL, though 2024–2025 fibroblast-specific data remain sparse and any figure used should be treated as model-dependent.
For thymosin β4-mimetic peptides such as TB500, actin-sequestration and fibroblast-migration endpoints are typically assessed over 12–48 hours, with G-actin binding confirmed by co-sedimentation assay.
Measurement Endpoints and Controls
Collagen synthesis is quantified by Sircol collagen assay or hydroxyproline content; gene expression via reverse transcription quantitative polymerase chain reaction (RT-qPCR) targeting COL1A1, COL3A1, and ELN. Antioxidant activity for glutathione studies is measured by 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB)-based GSH assay or Nrf2 reporter constructs.
Every experiment requires vehicle-only and untreated controls, with peptide-free solvent matched to the reconstitution buffer. Positive controls, ascorbic acid for collagen induction, for example, anchor the assay to published benchmarks. Batch-to-batch variability is a documented source of irreproducibility; lot-specific HPLC purity data should be recorded in the methods section of any publication.
Key Takeaways: Choosing the Right Peptide for Your Research
Matching your peptide to a specific mechanistic question is the most reliable way to design a reproducible in vitro study. The table below maps each peptide to its primary research endpoint, with sourcing and regulatory notes that apply under Australian conditions as of 2026.
| Research Question | Peptide | Primary Endpoint | Regulatory Note |
|---|---|---|---|
| Collagen synthesis / fibroblast activation | GHK-Cu | COL1A1/COL3A1 expression, Sircol assay | No ARTG listing for cosmetic use |
| Tissue repair / angiogenesis | BPC-157 | Wound closure, VEGF expression | Research-only; no TGA-approved indication |
| Cell migration / actin dynamics | TB500 | G-actin co-sedimentation, scratch assay | Research-only; not for human administration |
| Antioxidant / redox signalling | Glutathione | Nrf2 reporter, DTNB-based GSH assay | Parenteral cosmetic use subject to TGA scrutiny |
| Melanogenesis modulation | Melanotan II | Tyrosinase activity, melanin content | Schedule 4; advertising to public is illegal |
Sourcing and Purity Checklist
Before committing to a concentration protocol, confirm the following for every lot:
- Lot-specific HPLC purity data on file (≥95% is a common research-grade threshold, though GMP-certified clinical-grade material requires validated release testing under PIC/S standards)
- Certificate of Analysis includes identity confirmation (mass spectrometry or nuclear magnetic resonance) and residual solvent limits
- Supplier can provide batch traceability documentation
- Reconstitution buffer is matched across vehicle controls to eliminate solvent confounds
- For parenteral-grade material, endotoxin testing results are included in the batch record
Suppliers such as Body Pharm Australia provide research-grade peptides with documented analytical data; researchers should request lot-specific HPLC and mass spectrometry reports before finalising a concentration protocol.
Next Steps for Your Skin-Repair Research
All peptides listed here are for in vitro and preclinical research use only. None carry TGA approval for human therapeutic or cosmetic administration, and supply or promotion outside approved pathways may breach Australian medicines law.
To begin your research programme, select your primary endpoint (collagen synthesis, cell migration, melanin modulation, or antioxidant activity), identify the peptide that targets that pathway, and source research-grade material with verified HPLC purity and batch traceability from an Australian supplier. Consult the TGA's Special Access Scheme guidance and, where animal work is involved, obtain approval from an institutional Animal Ethics Committee before commencing experiments. Document lot-specific analytical data in your methods section to support reproducibility and future publication.